Form Bio

We’re heading to SynBioBeta, May 4–7, at the San Jose Convention Center! Find us in the Start-Up Pavilion at Booth #15. We empower synthetic biology teams to design, test, and scale engineered biological systems faster—by unifying AI-driven design, high-throughput genomic analysis, and manufacturing prediction. DM us on LinkedIn or in the app to meet up: Michelle Chen, Ph.D. - President & CEO Amicia D. Elliott, Ph.D. - VP, Product Angela Anderson - Head of Marketing https://www.formbio.com/ #Synbiobeta2026 #AI #geneticmedicine #genomeengineering #syntheticbiology

We’ll be at Biocom’s Converge Summit on April 23! Excited to share that Michelle Chen, Ph.D., CEO of Form Bio, will be speaking during the lightning talks from 1:30–1:55 PM. Talk: AI for Predictable and Scalable Biology Reach out to David Kiger to connect. #ConvergeSummit #BioTech #AI #CellandGeneTherapy

We’re hiring a Technical Program Manager (Bioinformatics) in Austin or Dallas (hybrid). Lead a flagship enterprise biotech engagement at the intersection of AI, genomics, and software—own the relationship, drive delivery, and turn science into impact. If you thrive in fast-paced, high-stakes environments and love bridging science + execution, let’s talk. Check out the JD: https://lnkd.in/g7h-SGaD #Bioinformatics #BiotechJobs #ComputationalBiology #DataScience #BiotechCareers #ProgramManager #AustinJobs #DallasJobs

We’ll be at Biocom’s Converge Summit on April 23, where Michelle Chen, Ph.D., CEO of Form Bio, will be speaking during the lightning talks from 1:30–1:55 PM. Looking forward to connecting! Learn More: https://lnkd.in/dFkGidfW #ConvergeSummit #Biotech #CellandGeneTherapy

I am looking forward to attending and speaking at #SynBioBeta2026 May 4-7 this year. I'll be participating in the panel "Data Factories: Building the Infrastructure for AI-Ready Biology", together with Michael Koeris, Chase Olle, Ori Zakin and Barry Bunin. Thanks John Cumbers for organizing this exciting event! Form Bio will have a table at the conference. Please stop by and talk to our team to explore collaborations! Angela Anderson Amicia D. Elliott, Ph.D. David Kiger Colossal Biosciences #AI #Engineered #biology #collaborations #syntheticbiology #planetary #impact

Gene therapy is advancing faster than ever. Despite major breakthroughs, 50+ approvals, rapid advances in gene editing, 2025 exposed real cracks: → Programs slowing or shutting down → Safety concerns surfacing in AAV and CRISPR → FDA decisions becoming harder to predict A recent editorial in Nature Medicine makes one thing clear: scientific progress alone isn’t enough. If we want this field to scale, we need to fix what surrounds it: – Early-stage investment – Transparent safety data (especially from failures) – Regulatory clarity The risk isn’t that gene therapy doesn’t work. It’s that the ecosystem around it isn’t keeping pace with the science. Read the full editorial: https://lnkd.in/g337NV89 #genetherapy #biotech #geneticmedicine #drugdevelopment #regulatoryscience

We’re heading to the 3rd International Human Gene Therapy Conference in Boston (March 23–25) and looking forward to connecting with the community. Catch Jeremy Shelley speaking on Monday, March 23 at 11:30am ET: “Optimizing Gene Therapy Development Through Long-Read Sequencing” If you’re attending, let’s meet up—feel free to reach out! 📍 Hilton Boston Back Bay 🔗 https://lnkd.in/gKu-bQ3F #GeneTherapy #BiotechEvents #BiotechInnovation

🎙 What happens when a personal mission becomes a new model for drug development? In our latest episode of The Algorithm of Life, Form Bio CEO Michelle Chen, Ph.D.  speaks with Rich Horgan, Founder of the Cure Rare Disease Foundation, about how one family’s search for answers helped spark a movement to accelerate therapies for ultra-rare diseases. Their conversation explores how the field is evolving, from N-of-one therapies developed for a single patient to the possibility of building scalable pipelines for rare disease treatments. With 300M+ people worldwide living with rare diseases, the path forward will require new models, new partnerships, and a relentless focus on patients. 🎧 Listen to the episode: Apple: https://lnkd.in/gQKTAGaK Spotify: https://lnkd.in/g4vKk7py

Rare diseases impact more than 300 million people worldwide, yet many patients still face limited treatment options and long diagnostic journeys. In our inaugural podcast, Michelle Chen, Ph.D., CEO of Form Bio, sits down with Rich Horgan, Founder & CEO of the Cure Rare Disease Foundation, to share a deeply personal story that became a mission, accelerating gene and cell therapy development for ultra-rare diseases. The conversation explores: - The patient journey that inspired Cure Rare Disease - The rise of foundation-led drug development - The realities of gene therapy manufacturing cost and scalability, and how AI / technology may change that - Why collaboration and transparency are critical to progress As we reflect on Rare Disease Day, this discussion is a reminder that innovation is ultimately about patients, families, and communities working together to create hope. 🎧  Listen to the full podcast here: Apple: https://lnkd.in/gQKTAGaK Spotify: https://lnkd.in/gHwTTSCv #RareDiseaseDay #RareDisease #ShowYourStripes #GeneTherapy #GeneticMedicine #podcast #lifesciences #AI

🔥Exciting publication alert! AlphaGenome, published in Nature by Google DeepMind represents a major milestone in genomic AI, building on nearly a decade of incremental progress toward unified, sequence-to-function modeling of regulatory biology. This isn’t a revolution from nowhere. It is the latest evolution in a lineage of models - from Enformer to Borzoi, each pushing the boundaries of input size, output resolution, and modality coverage. What AlphaGenome adds is significant: explicit splice junction and usage prediction, 3D chromatin contact maps, and single base-pair resolution across a million base-pair input window. Taken together, that is a meaningful architectural advancement over its predecessors. Key takeaways: 🔬 Unified multimodal prediction Genomic sequence models are often trained to predict a single function: One model for splicing, another for chromatin, another for expression. AlphaGenome integrates these into a single model, generating a unified map of regulatory function directly from sequence. This multi-task approach helps the model learn the many faceted genomic language supporting biology. AlphaGenome integrates gene expression, splicing, chromatin accessibility, histone modifications, transcription factor binding, and 3D genome organization into a single model. The new splicing and contact map modalities as well as larger input window allows for learning long range regulatory interactions that would not be possible in previous models.This is genuinely useful for predicting genomic variant effects and provides the next milestone in sequence to function models like Borzoi and Enformere. 🧬 Long-range, base-pair precision Earlier models typically captured either short windows (missing distal regulation) or long windows at lower resolution. AlphaGenome achieves both long-range context and base-level precision — critical for decoding complex regulatory interactions. 🧠 Improved variant interpretation By scoring how subtle sequence changes ripple across multiple biological layers, the model advances our ability to understand disease mechanisms, non-coding risk variants, therapeutic targets, and prioritization of genetic edits. While not a clinical diagnostic tool, this marks a meaningful step toward computationally interpreting the genome at scale. Read the paper: https://hubs.li/Q045q3hj0 #AI #genomics #geneticmedicine